Non-Squamous Non-Small Cell Lung Cancer Completed Phase 3 Trials for Bevacizumab (DB00112)

Also known as: Non-squamous Non-small Cell Lung Cancer

IndicationStatusPhase
DBCOND0036730 (Non-Squamous Non-Small Cell Lung Cancer)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03169335Efficacy and Safety of QL1101 and AvastinĀ® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung CancerTreatment
NCT01364012A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous ChemotherapyTreatment
NCT01351415A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)Treatment
NCT00806923A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Treatment
NCT00976456Efficacy Study of AvastinĀ® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung CancerTreatment
NCT00961415AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung CancerTreatment